Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer

Abstract Context Second‐generation androgen receptor inhibitors (ARIs) extend metastasis‐free survival, prolong overall survival, and delay symptoms when added to androgen deprivation therapy for the treatment of castration‐sensitive or castration‐resistant prostate cancer (CRPC). However, ARIs may...

Full description

Bibliographic Details
Main Authors: Tomasz M. Beer, Neal Shore, Alicia Morgans, Kerri Winters‐Stone, Jeffrey S. Wefel, Daniel J. George
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:BJUI Compass
Subjects:
Online Access:https://doi.org/10.1002/bco2.179